(9ci)-4,5,6,7-四甲基-1H-苯并咪唑 | 106148-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: (9ci)-4,5,6,7-四甲基-1H-苯并咪唑
• 英文名称: 4,5,6,7-tetramethylbenzimidazole
• 英文别名: 4,5,6,7-Tetramethyl-1H-benzimidazole
• CAS: 106148-67-8
• 化学式: C₁₁H₁₄N₂
• mdl: MFCD00460108
• 分子量: 174.246
• InChiKey: DNTYIZWXLLFMLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  4,7-di(chloromethyl)-5,6-dimethylbenzo-2,1,3-thiadiazole 在 盐酸 、 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 29.0h， 生成 (9ci)-4,5,6,7-四甲基-1H-苯并咪唑
  参考文献：
  名称：

  D'yachenko, E. K.; Pesin, V. G.; Papirnik, M. P., Journal of Organic Chemistry USSR (English Translation), 1986, vol. 22, p. 372 - 375

  摘要：

  DOI：

文献信息

• HETERO COMPOUND
  申请人：HARADA Hironori

  公开号：US20090076070A1

  公开（公告）日：2009-03-19

  [Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P 1 agonist activity. [Means for Solving] Since the compound of the invention has an S1P 1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.

  [问题] 提供一种有优异S1P1激动剂活性的化合物，作为器官、骨髓或组织移植、自身免疫性疾病等引起的排异的预防和/或治疗剂的有效活性成分。 [解决方法] 由于本发明的化合物具有S1P1激动剂活性，因此可用作治疗或预防由不良淋巴细胞浸润引起的疾病的活性成分，例如器官、骨髓或组织移植的移植排斥、移植物抗宿主病、风湿性关节炎、多发性硬化症、全身性红斑狼疮、肾病综合症、脑脊髓炎、重症肌无力、胰腺炎、肝炎、肾炎、糖尿病、肺部疾病、哮喘、特应性皮炎、炎症性肠病、动脉粥样硬化、缺血再灌注损伤或异常细胞生长或积累引起的癌症和白血病等疾病。
• Synthesis and activity of 1H-benzimidazole and 1H-benzotriazole derivatives as inhibitors of Acanthamoeba castellanii
  作者：Katarzyna Kopańska (née Zastąpiło)、Andżelika Najda、Justyna Żebrowska、Lidia Chomicz、Janusz Piekarczyk、Przemysław Myjak、Maria Bretner

  DOI：10.1016/j.bmc.2004.03.022

  日期：2004.5

  Chloro-, bromo- and methyl- analogues of 1H-benzimidazole and 1H-benzotriazole and their N-alkyl derivatives have been synthesized and tested in vitro against the protozoa Acanthamoeba castellanii. The results indicate that 5,6-dimethyl-1H-benzotriazole (11) and 5,6-dibromo-1H-benzotriazole (14) have higher efficacy than the antiprotozoal agent chlorohexidine. (C) 2004 Elsevier Ltd. All rights reserved.
• DYACHENKO, E. K.;PESIN, V. G.;PAPIRNIK, M. P., ZH. ORGAN. XIMII, 1986, 22, N 2, 421-424
  作者：DYACHENKO, E. K.、PESIN, V. G.、PAPIRNIK, M. P.

  DOI：——

  日期：——
• US7678820B2
  申请人：——

  公开号：US7678820B2

  公开（公告）日：2010-03-16
• US7951825B2
  申请人：——

  公开号：US7951825B2

  公开（公告）日：2011-05-31